0
0
Loading version...
🔄 Update App
🔍 Check for Updates
Test Notification
🔔 Enable Notifications
📰 Fetch NHK News
🚀 Fetch TechCrunch News
🧪 Experiment
📰 Article Management
📚 Reading List
🎤 Speaking List
📊 Statistics
💻 Software Statistics
Push Admin
Edit Reading
Back to List
Basic Information
Title
Please enter a title.
URL
Please enter a valid URL.
Date
カテゴリID
画像ファイル名
統計情報
単語数:
156語
読了回数:
0回
作成日:
2022/03/30 19:51
更新日:
2025/12/09 17:21
本文
本文
NHK has learned that a third-party committee of experts has found no safety problems so far with a procedure to repair spinal cord injuries by transplanting cells derived from induced pluripotent stem cells, or iPS cells. A team led by Okano Hideyuki and Nakamura Masaya, both professors at Keio University, performed the world's first procedure in December. They transplanted iPS-derived nerve cells into a patient whose spinal cord had been damaged. The team submitted data on the patient to the Independent Data Monitoring Committee. The committee concluded on Tuesday that the patient has so far not shown any grave side effects, and gave the go-ahead for a second clinical trial. The committee did not assess the medical effect of the transplant, as it plans to monitor this aspect over the course of one year. The team plans to transplant iPS-derived cells into four patients. They will start accepting applications next month for their second clinical trial.
本文を入力してください。
メモ
メモ・感想
キャンセル
更新
Debug Info:
Saved State:
-
Redirected Flag:
-
Current URL:
-
Refresh
Close
Debug
Send Report
Send Report
Draw Arrow
Clear
Message:
Cancel
Send